What kind of people are "engines"? Studies show that they are more likely to be psychopaths, sadists, and narcissists.

Published Date: 17 Feb 2023

Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

Accurate and Timely Diagnosis of Endometriosis

Accurate and Timely Diagnosis of Endometriosis

Bridging Specialties to Manage Hyperglycemia in Breast Cancer Patients Treated With PI3K/AKT Pathway Inhibitors

Bridging Specialties to Manage Hyperglycemia in Breast Cancer Patients Treated With PI3K/AKT Pathway Inhibitors

Recognizing the Multifactorial Barriers to Effective Weight Loss in Obesity

Recognizing the Multifactorial Barriers to Effective Weight Loss in Obesity

From Crisis to Control: Strategies to Address Recurrent Severe Hypoglycemia in Type 1 Diabetes

From Crisis to Control: Strategies to Address Recurrent Severe Hypoglycemia in Type 1 Diabetes

Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities

Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities

Doctors Urge Women to Be Wary of Marketing Surge in Menopause Products

"It really pays to be very, very, very skeptical," says one expert

Many Older Patients Can Ditch Common Thyroid Drug, Study Suggests

Experts call for better guidance on levothyroxine initiation, deprescribing

Todays Updates

Accurate and Timely Diagnosis of Endometriosis

Accurate and Timely Diagnosis of Endometriosis

Bridging Specialties to Manage Hyperglycemia in Breast Cancer Patients Treated With PI3K/AKT Pathway Inhibitors

Bridging Specialties to Manage Hyperglycemia in Breast Cancer Patients Treated With PI3K/AKT Pathway Inhibitors

Recognizing the Multifactorial Barriers to Effective Weight Loss in Obesity

Recognizing the Multifactorial Barriers to Effective Weight Loss in Obesity

From Crisis to Control: Strategies to Address Recurrent Severe Hypoglycemia in Type 1 Diabetes

From Crisis to Control: Strategies to Address Recurrent Severe Hypoglycemia in Type 1 Diabetes

Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities

Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities

Doctors Urge Women to Be Wary of Marketing Surge in Menopause Products

"It really pays to be very, very, very skeptical," says one expert

Many Older Patients Can Ditch Common Thyroid Drug, Study Suggests

Experts call for better guidance on levothyroxine initiation, deprescribing

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

African American men see biggest survival gain from healthier lifestyles post prostate cancer diagnosis

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

Drug-chemo combo increases cancer treatment efficacy

Cancer care crowdfunding increasingly common, but rarely successful

Recommended Articles For You

The New Era of Oncology: Key Updates and Clinical Insights 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

The latest Hematocrit: An Overview of Red Blood Cell Health  

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs

2.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

3.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

4.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

5.

Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.

1.

Organoids & Single-Cell Tools: Breakthroughs in Colorectal Cancer Research

2.

AI-Powered Rehabilitation: A Game Changer for Hemophilia Management

3.

Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook

4.

From Bench to Bedside: The New Era of Lymphoma Treatment and Education

5.

Uncovering the Hidden Gallons: How Much Blood Is Inside the Human Body?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

2.

Navigating the Complexities of Ph Negative ALL - Part VIII

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

4.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot